Event Summary: U.S. Med‑Tech Innovation and Europe’s Growing Role
By John Moetteli, Secretary, AIC Geneva
The American International Club of Geneva hosted an insightful luncheon on January 28, 2026, at the Hôtel Royal, featuring med‑tech entrepreneur Jim Buck, CEO at Medcura and seasoned leader across multiple successful medical‑device ventures.
Buck highlighted the rapidly evolving landscape of U.S. life‑sciences innovation, where disciplined capital markets and outcome‑focused regulators are reshaping how new medical technologies come to market. Drawing from Medcura’s work in biosurgery, he offered practical advice on navigating FDA approval, emphasizing early engagement, strong clinical evidence, and clear demonstrations of patient benefit.
A key theme—was the growing convergence between FDA and EMA requirements. Buck noted that both authorities increasingly prioritize meaningful clinical improvements and robust safety data, allowing innovators to design trials that serve both regulatory frameworks more efficiently.
He also underscored the strategic value of combining U.S. venture‑capital rigor with Europe’s deep technical expertise and expanding investment appetite. According to Buck, the next generation of global healthcare leaders will be those who understand and operate effectively across both ecosystems.
His talk was highly engaging and especially valuable for its actionable insights into the realities of bringing medical technologies to market on both sides of the Atlantic. Jim Buck’s perspective made clear that the future of med‑tech innovation belongs to those who embrace the increasingly interconnected U.S.–European landscape.